bioRxiv Science⌕ Search

Biology subjects

Robledo, P.

Publications and source records attributed to Robledo, P..

2 recordsLinked to original sources

Mesenchymal predominance in olfactory epithelium-derived cultures limits modeling of neurodevelopmental brain disorders

The human olfactory epithelium (OE) represents a lifelong source of neural progenitor cells and has been proposed as an accessible model to investigate molecular alterations associated with neurodevelopmental disorders in postnatal individuals. Globose basal cells are considered the immediate neuronal progenitors within the OE, and several studies have attempted to culture these cells from nasal exfoliates. However, the actual contribution of neurogenic lineages in these cultures remains largely unquantified. Here, we cultured human nasal explants using an established protocol and characterized the resulting cell populations by immunohistochemistry and single-cell RNA sequencing. Integration with primary in vivo OE datasets revealed that these cultures are predominantly composed of mesenchymal-like cells, with limited representation of globose basal cells and neurons, and low expression of canonical neuronal markers. Using curated gene sets associated with neurodevelopmental disorders and malformations of cortical development, we assessed the extent to which disease-relevant transcriptional programs are captured in OE-derived cultures. While disease-associated genes are enriched in neurogenic lineages in vivo, their representation in mesenchymal cells is reduced. Together, our results challenge the assumption that standard OE culture systems faithfully model neurogenic compartments and suggest that current approaches may need refinement to recover neurogenic lineages.

neuroscience↗

2-AG as a potential biomarker for predicting response to short-term fluoxetine treatment in a mouse model of depression

Major depressive disorder (MDD) is a complex psychiatric condition with significant individual and social impact and marked variability in treatment response. Identifying biomarkers that predict antidepressant efficacy remains a major challenge, and metabolomic approaches offer a powerful tool to uncover biochemical changes associated with depression and treatment outcome. The prefrontal cortex and the hippocampus are key brain regions involved in the pathophysiology of MDD and antidepressant response. Fluoxetine, one of the most commonly prescribed antidepressants, influences not only serotonergic signaling but also the endocannabinoid system. Accordingly, evaluating endocannabinoid levels in these brain regions might provide critical insight into their contribution to mood disorders and the effect of fluoxetine. To identify biomarkers associated with early antidepressant response, male mice were exposed for 5 weeks to the unpredictable chronic mild stress (UCMS) protocol, with fluoxetine treatment administered during the final week. Liquid chromatography-tandem mass spectrometry analyses of hippocampal and prefrontal cortex samples revealed that the depression-like phenotype induced by UCMS was associated with increased hippocampal anandamide (AEA) levels. Behavioral improvement following short-term fluoxetine treatment was accompanied by enhanced hippocampal 2-arachidonoylglycerol (2-AG), which was associated with reduced GABA and glutamate levels in the prefrontal cortex. These findings suggest that increased 2-AG levels may serve as a predictor of early response to fluoxetine.

neuroscience↗